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Mammalian target of rapamycin (mTOR) has been
implicated in human neurological diseases such
as tuberous sclerosis complex (TSC), neurodegen-
eration, and autism. However, little is known about
when and howmTOR is involved in the pathogenesis
of these diseases, due to a lack of animal models
that directly increase mTOR activity. Here, we gener-
ated transgenic mice expressing a gain-of-function
mutant of mTOR in the forebrain in a temporally
controlled manner. Selective activation of mTORC1
in embryonic stages induced cortical atrophy caused
by prominent apoptosis of neuronal progenitors,
associated with upregulation of HIF-1a. In striking
contrast, activation of themTORC1 pathway in adult-
hood resulted in cortical hypertrophy with fatal
epileptic seizures, recapitulating human TSC. Acti-
vated mTORC1 in the adult cortex also promoted
rapid accumulation of cytoplasmic inclusions and
activation of microglial cells, indicative of progres-
sive neurodegeneration. Our findings demonstrate
that mTORC1 plays different roles in developmental
and adult stages and contributes to human neurolog-
ical diseases.INTRODUCTION
Mammalian (or mechanistic) target of rapamycin (mTOR) is an
evolutionarily conserved serine/threonine kinase that regulates
cellular metabolism in response tomultiple environmental stimuli,
such as growth factors and amino acids, as well as energy avail-
ability (Laplante and Sabatini, 2012; Wullschleger et al., 2006).
mTOR functions in two structurally distinct protein complexes,
named mTOR complex 1 (mTORC1) and mTORC2. Activation of
the mTORC1 pathway facilitates protein synthesis via phosphor-
ylation of p70S6 kinase (S6K1 andS6K2) and eukaryotic initiation1626 Cell Reports 7, 1626–1639, June 12, 2014 ª2014 The Authorsfactor 4-binding protein (4EBP1 and 4EBP2). Concurrently, acti-
vated mTORC1 suppresses protein degradation by inhibiting
the autophagic pathway. Thus, mTORC1 signaling integrates a
wide variety of cellular processes, including cell growth, prolifera-
tion, and survival, by coupling and balancing anabolic and cata-
bolic states.
The importance of mTOR for cellular function is reflected in
the association of dysregulated mTOR signaling with human dis-
eases such as cancer, diabetes, and obesity (Cornu et al., 2013;
Laplante and Sabatini, 2012; Yang et al., 2012). Accumulating ev-
idencedemonstrates thatmTORalsoplaysakey role inquiescent
cells, especially in neurons. Loss of function of mTOR signaling
causes impairment of axon guidance, dendritic arborization,
and synaptic plasticity in cultured neurons (Jaworski and Sheng,
2006; Swiech et al., 2008), and hypomyelination inmicewith con-
ditional knockout of the small G-protein Rheb1, a proximal acti-
vator of mTORC1 (Yamagata et al., 1994; Zou et al., 2011). In
the human CNS, dysregulation of mTOR signaling is observed
in various neurological and neuropsychiatric disorders, such as
neurodegenerative diseases (Bove´ et al., 2011; Reith et al.,
2011), tuberous sclerosis complex (TSC) (Orlova and Crino,
2010), fragile X syndrome (Busquets-Garcia et al., 2013; Sharma
et al., 2010), and autism (Sato et al., 2012; Tsai et al., 2012).
Neurodegenerative diseases, such as Alzheimer’s, Huntington’s,
and Parkinson’s diseases, are characterized by accumulation
of misfolded protein aggregates called cytoplasmic inclusions,
which leads to cellular damage and a functional loss of neurons
(Bove´ et al., 2011). Administration of rapamycin to amousemodel
of neurodegenerative diseases ameliorates neuronal cell death
(Ravikumar et al., 2004), suggesting that activation of mTOR
is involved in the progression of these diseases, presumably by
suppressing autophagic degradation of inclusions. TSC is an
autosomal-dominant genetic disorder caused by mutations in
either the TSC1 or TSC2 gene (Orlova and Crino, 2010). TSC1
and TSC2 negatively control mTORC1 activity by forming a
heterodimer that acts as a GTPase-activating protein for Rheb.
TSC pathology is characterized by nonmalignant tumors called
hamartomas in many organs. The neurological manifestation of
TSC is hamartomatous lesionscalled cortical tubers, subependy-
mal nodules, and subependymal giant cell astrocytomas. These
brain lesions are assumed to induce neuropsychiatric symptoms
such as epileptic seizure, autism, and mental retardation in TSC
patients.
Importantly, as is the casewith human cancer,mTORsignaling
is consistently hyperactivated but not suppressed in mTOR-
related neurological disorders. In the case of TSC, conditional
knockout mice deficient in Tsc1 or Tsc2 in various brain regions
have been developed so as to recapitulate TSC pathogenesis.
In the cerebral cortex, conditional knockout mice of Tsc1 have
shown epileptic seizures, premature death, and abnormal cy-
toarchitecture of the forebrain, including the cerebral cortex
and hippocampus (Carson et al., 2012; Magri et al., 2011; Meikle
et al., 2007; Way et al., 2009; Zhou et al., 2011). However,
because mTORC1 can be regulated independently of TSC1/2,
the extent towhichmTORactivation is involved in the pathogenic
mechanisms of TSC has been unclear. For example, AMP-acti-
vated protein kinase directly phosphorylates raptor, a compo-
nent of mTORC1, leading to inhibition of mTORC1 signaling
(Gwinn et al., 2008). Akt also regulates mTORC1 activity in
a TSC1/2-independent manner by phosphorylating PRAS40,
an mTORC1 inhibitor (Sancak et al., 2007; Vander Haar et al.,
2007; Wang et al., 2007). In addition, mTOR function in the
developing brain, where neuronal progenitors actively undergo
proliferation,may differ from that in themature brain, where post-
mitotic neurons exert diverse neurological functions. Therefore, it
has been difficult to address when and how mTOR activation
is important for brain development and functions, as well as the
pathogenesis of human diseases.
In this study, we demonstrate that mTORC1 signaling plays
different physiological roles in developing and mature brains.
We established transgenic (Tg) mice lines carrying mTOR kinase
with gain-of-function mutations that direct selective activation of
the mTORC1 pathway in a spatially and temporally controlled
manner. Mutant mice expressing active mTOR kinase in the
embryonic cortex displayed progressive apoptotic cell death of
neuronal progenitors, resulting in cortical atrophy. In marked
contrast, mTORC1 activation in postmitotic neurons in both
juvenile and adult mice led to cortical hypertrophy and severe
epileptic seizures. Concomitantly, cytoplasmic inclusions rapidly
accumulated in the cortical neurons after chronic activation
of mTORC1, indicative of neurodegeneration. Our data pro-
vide direct evidence that stage-specific activation of mTORC1
signaling faithfully recapitulates human microcephaly, TSC,
and neurodegenerative diseases.
RESULTS
Embryonic Activation of the mTOR Pathway
For chronic activation of themTOR pathway, we used a hyperac-
tive mutant of rat mTOR kinase (mTORSL1+IT), which harbors four
point mutations in the FRB (FKBP12-rapamycin binding) and
kinase domains, and is tagged with the FLAG epitope at its N ter-
minus (Ohne et al., 2008). In cultured cells, active mTOR keeps
enhanced kinase activity specifically toward mTORC1 sub-
strates such as S6K1 and 4EBP1 even under starvation condi-
tions, but its kinase activity is sensitive to rapamycin. In contrast,
the kinase activity toward the mTORC2 substrate Akt1 is hardly
retained under starvation conditions (Ohne et al., 2008). Hyper-Cactivation of the mTORC1 pathway, but not mTORC2, was
also observed in the Tg mice used in this study (see Figures
4D, S4A, and S4B). We established a line of Tg mice in which
mTORSL1+IT is placed under control of the ubiquitous CAG pro-
moter, but its expression was subjected to interference by the
loxP-flanked neo gene (CAG-mTORSL1+IT; Figure 1A). Therefore,
active mTOR can be conditionally expressed upon excision of
the neo gene in response to Cre-loxP recombination. These Tg
mice (CAG-mTORSL1+IT/+) were crossed with Emx1-cre knockin
mice (Emx1cre/+) to obtain CAG-mTORSL1+IT/+; Emx1cre/+ mice
(Kassai et al., 2008). Emx1-cre mice express Cre recombinase
exclusively in the dorsal telencephalon (Figure 1B) as early as
embryonic day 10 (E10). Emx1-lineage neuronal progenitor cells
in the dorsal telencephalon give rise to almost all projection
neurons as well as a subset of glial cells in the cerebral cortex
and hippocampus in adulthood. Thus, active mTOR is assumed
to be expressed in these brain regions during cortical
development in CAG-mTORSL1+IT/+; Emx1cre/+ mice. Hereafter,
CAG-mTORSL1+IT/+; Emx1cre/+ mice are referred to as Emx1-
mTOR Tg mice. CAG-mTORSL1+IT/+ mice were used for the
experimental control animals.
Decreased Cortical Size in Emx1-mTOR Tg Mice
Emx1-mTOR Tg mice were obtained at the expected Mendelian
ratio and survived to adulthood without gross abnormalities
in their appearance. However, the cerebral cortex of Emx1-
mTOR Tg mice was remarkably atrophied in adulthood (Figures
1C and 1D). Despite a reduction in its size, the cortical structure
was almost preserved with a six-layered cytoarchitecture, as
revealed by immunohistochemical distribution of Cux1- and
FoxP2-positive neurons located at layers II/III and layer VI,
respectively (Figures 1E and 1F). The hippocampus of Emx1-
mTOR Tg mice was also smaller than that of control mice (Fig-
ures 1D and S1), but other brain regions lacking Cre expression
were almost unaffected by the genotype (Figures 1C and 1D).
Interestingly, protein expression of active mTOR was undetect-
able in the cortical lysate of Emx1-mTOR Tg mice in adulthood
(Figure S2), suggesting that most of the activemTOR-expressing
cells underwent cell death during corticogenesis. When the
Emx1-mTOR Tg mice were examined at embryonic stages,
cortical atrophy was already obvious at E12 without affecting
the morphology of lateral and medial ganglionic eminences,
where cortical interneurons are generated (Figures 2A–2C).
These results indicate that embryonic activation of mTORC1 re-
duces the cortical size during corticogenesis.
Neuronal Progenitor Cell Death in Emx1-mTOR Tg
Cortex
Given that the cortical size was decreased by the expression of
active mTOR, we examined cell proliferation and survival of
neuronal progenitor cells in Emx1-mTOR Tg cortex at E12.
Neuronal progenitor cells in M phase of the cell cycle divide at
the apical surface of the ventricular zone. These dividing cells
can be marked by phosphorylated histone H3 (pH3) immunore-
activity. The number of pH3-positive cells was not significantly
different between control and Emx1-mTOR Tg cortices (Figures
2D–2F), indicating that proliferation of neuronal progenitor cells
was not affected by the activation of mTORC1 pathway. Next,ell Reports 7, 1626–1639, June 12, 2014 ª2014 The Authors 1627
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Figure 1. Activation of the mTOR Pathway
in Embryonic Dorsal Telencephalon
(A) Transgenic strategy for conditional expression
of active mTOR kinase by the Cre-loxP system.
Excision of the floxed neo gene by Cre re-
combinase induces active mTOR expression
driven by the CAG promoter. The cre gene is
inserted into the endogenous Emx1 locus for
expression in the embryonic dorsal telencephalon
of Emx1-cre knockin mice.
(B) Expression patterns of Cre recombinase in
Emx1-cre knockin mice. Emx1-cre knockin mice
were crossed with Cre-activatable lacZ reporter
mice, and brain sections were stained with X-gal.
Cre expression was readily detectable and
restricted in the dorsal telencephalon at E12. Note
that Cre expression is absent in the lateral
ganglionic eminence (LGE) and medial ganglionic
eminence (MGE), where cortical interneurons are
generated and migrate into the neocortex.
(C and D) Decreased cortical size of Emx1-mTOR
Tg brain in adulthood. Control and Emx1-mTOR
Tg brains were fixed and isolated at 8 weeks
of age. Sagittal brain sections were stained with
cresyl violet.
(E and F) Thinned but normal cortical layer in
Emx1-mTOR Tg mice. Cortical sections at
8 weeks of age were immunostained with Cux1
(E, layer II/III) or FoxP2 (F, layer VI). Cb, cere-
bellum; Cx, cerebral cortex; Hp, hippocampus;
LGE, lateral ganglionic eminence; LV, lateral
ventricle; MGE, medial ganglionic eminence; OB,
olfactory bulb; SC, spinal cord; Th, thalamus.
Scale bars, 500 mm (B), 1 mm (D) and 100 mm
(E and F). See also Figures S1 and S2.to determine the cause of neuronal cell loss, we examined
apoptotic cell death by immunohistochemical staining of
cleaved caspase 3 (CC3). A significant increase of CC3 immuno-
reactivity was detected in Emx1-mTORTg cortex comparedwith
the control at E12 (Figures 2G–2I). The CC3-positive area almost
overlapped with pyknotic nuclei (Figure 2H), another character-
istic feature of apoptosis. The apoptotic cells were also merged
with FLAG-positive cells (Figure S3), indicating that active mTOR
is expressed in the dying cells. As CC3-positive cells with py-1628 Cell Reports 7, 1626–1639, June 12, 2014 ª2014 The Authorsknotic nuclei were mainly localized at
the subventricular zone (SVZ) of the cor-
tex, we tested whether the survival of
SVZ progenitors was sensitive to activa-
tion of mTORC1 signaling. As expected,
the number of Tbr2-positive SVZ pro-
genitors was significantly decreased in
Emx1-mTOR Tg mice (Figures 2J–2L).
Together, these results indicate that acti-
vation of themTORC1 pathway promotes
apoptotic cell death of neuronal progeni-
tors without affecting their proliferation
during corticogenesis.
We explored mTOR-regulated down-
stream effectors that triggered theapoptotic cell death of neuronal progenitors. Hypoxia-inducible
factor 1a (HIF-1a) is a transcription factor that is responsible
for oxygen sensing (Sharp and Bernaudin, 2004) and is impli-
cated in apoptotic signaling (Carmeliet et al., 1998). HIF-1a
is rapidly ubiquitinylated and degraded by the proteasome
under normoxic conditions. In hypoxia, HIF-1a is stabilized and
forms a complex with HIF-1b to activate expression of target
genes related to angiogenesis and apoptosis (Sharp and Ber-
naudin, 2004). Activation of the mTOR pathway is involved in
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Figure 2. Apoptotic Cell Death of Neuronal
Progenitors by Embryonic Activation of the
mTOR Pathway
(A–C) Reduced cortical thickness in Emx1-mTOR
Tg embryo. Coronal sections from control (A) and
Emx1-mTOR Tg (B) brains at E12 were stained
with TO-PRO-3.
(D–F) Normal proliferation of neuronal progenitors
in Emx1-mTOR Tg cortex. M phase progenitor
cells of E12 cortex were marked with anti-phos-
pho-histone H3 antibody. The number of M phase
progenitors at the ventricular surface was not
significantly different between two genotypes.
(G–I) Increased apoptotic cell death of neuronal
progenitors by activation of the mTOR pathway.
CC3-positive cells were markedly increased in
Emx1-mTOR Tg cortex at E12 (H), but were almost
undetectable in control cortex (G). The CC3-
immunopositive area was quantified as the per-
centage relative to the corresponding total cortical
area (I).
(J–L) Loss of Tbr2-positive SVZ progenitors
in Emx1-mTOR Tg mice. Tbr2-positive cells were
quantified as the number of cells found in a certain
width (100 mm) of the cortex along the medial-
lateral axis. Values are means ± SD. *p < 0.005,
Student’s t test (n = 3). N.S., not significant.
Scale bars, 200 mm (A and B) and 20 mm (D, E, G,
H, J, and K). See also Figure S3.oxygen-independent regulation of HIF-1a expression by
increasing both the translation and stabilization of HIF-1a
(Land and Tee, 2007). In Emx1-mTOR Tg cortex at E12, we
found that the expression of HIF-1a was remarkably elevated
compared with the control (Figures 3A, 3D, and 3H). HIF-1a
expression almost overlapped with CC3-positive apoptotic cells
(Figures 3D–3F), suggesting that neuronal progenitor cell deathCell Reports 7, 1626–163may be mediated by HIF-1 signaling. To
further confirm activation of the HIF-1
pathway, we examined the expression
of the HIF-1 target gene in E12 cortex.
We observed prominent induction of
p21 (also termed cyclin-dependent ki-
nase inhibitor 1A) protein expression in
Emx1-mTOR Tg cortex in the corre-
sponding cortical area where HIF-1a
expression was upregulated (Figures 3G
and 3H). Thus, HIF-1 induction through
mTORC1 activation may contribute to
increased apoptotic cell death in Emx1-
mTOR Tg mice during corticogenesis.
Activation of mTORC1 Signaling in
Postmitotic Neurons
Because mTORC1 activation in the em-
bryonic cortex leads to apoptotic progen-
itor cell death, we established another
line of Tg mice to analyze mTOR function
in a spatially and temporally controlled
manner. In the new line of Tg mice,mTORSL1+IT is linked to tetracycline-responsive element
(TRE), and thus its expression can be regulated by tetracy-
cline-controlled transactivator (tTA; Figure 4A). These Tg mice
(TRE-mTORSL1+IT/+) were crossed with CaMKII-tTA Tg mice
(CaMKII-tTA/+) in which tTA is driven by the CaMKII promoter
and is expressed in postmitotic excitatory neurons in the
forebrain from the late embryonic or early postnatal period9, June 12, 2014 ª2014 The Authors 1629
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Figure 3. Altered HIF-1 Signaling by
mTORC1 Activation in the Embryonic
Cortex
(A–F) Increased expression of HIF-1a in Emx1-
mTOR Tg cortex. Coronal sections from control
(A–C) and Emx1-mTOR Tg brains (D–F) at E12
were immunostained with antibodies against HIF-
1a (green in A and D) andCC3 (red in B and E). HIF-
1a and CC3 signals are merged with nuclear
staining (C and F).
(G) Induction of p21 expression in Emx1-mTOR Tg
mice. Expression of p21, the HIF-1 target gene,
was markedly increased and overlapped with the
CC3-positive area in Emx1-mTOR Tg mice at E12.
(H) Quantification of HIF-1a and p21 signals in the
embryonic cortex. The immunopositive area of
each protein was expressed as a percentage of
the corresponding total cortical area. *p < 0.01,
**p < 0.005, Student’s t test (n = 3). Scale bars,
20 mm.(Mayford et al., 1996). Without doxycycline administration,
TRE-mTORSL1+IT/+; CaMKII-tTA/+ mice (hereafter designated
CaMKII-mTOR Dox() Tg mice) exhibited severe growth retar-
dation from postnatal day 10 (P10) and died at 15–20 days of
age (Figure 4B).
In CaMKII-mTOR Dox() Tg cortex, active mTOR expression
was increased postnatally and reached the maximum expres-
sion level around P10 (Figure 4C). Hyperactivation of the
mTORC1 pathway was confirmed by enhanced phosphorylation
level of S6K1 at Thr389 in the cortical lysate from CaMKII-mTOR
Dox() Tg mice compared with that from the control (Figure 4D).
The regional specificity of activemTOR expression was analyzed
by immunohistochemical localization of phosphorylated ribo-
somal S6 protein, a downstream target of S6K1. We detected
intense staining for phosphorylated Ser-235/236 of S6 protein1630 Cell Reports 7, 1626–1639, June 12, 2014 ª2014 The Authorsin the cerebral cortex and hippocampus
of CaMKII-mTOR Dox() Tg brain (Fig-
ures 4E and 4F). These expression pro-
files are consistent with spatiotemporal
distribution of tTA expression in CaMKII-
tTA Tg mice (Mayford et al., 1996), and
thus the mTORC1 pathway should be
activated in postmitotic neurons of the
forebrain in CaMKII-mTOR Dox() Tg
mice. It is noteworthy that the phosphor-
ylation level of Akt at Ser-473 in CaMKII-
mTOR Dox() Tg cortex was not different
from that in the control (Figure 4D), sug-
gesting that the mTORC2 pathway was
almost unaffected by the expression of
active mTOR.
Impaired Neuronal Migration and
Cell Size Regulation by mTORC1
Activation
Previous studies showed that loss of the
Pten or Tsc1 gene in the telencephalonleads to postnatal hypertrophy of the cerebral cortex and cortical
neurons (Carson et al., 2012; Groszer et al., 2001; Magri et al.,
2011;Meikle et al., 2007;Way et al., 2009; Zhou et al., 2011), pre-
sumably due to activation of mTOR signaling. We assessed
whether direct and selective activation of mTORC1 pathway
alters the cortical size and structure in CaMKII-mTOR Tg
Dox() mice. Despite the growth retardation, CaMKII-mTOR
Dox() Tg displayed cortical hypertrophy at P12 (Figures 4G–
4J). Both the cortical thickness (control: 0.86 ± 0.06 mm; Tg:
1.36 ± 0.06mm; Figures 4G, 4I, and 4K) and soma size of cortical
neurons (control: 62.7 ± 11.4 mm2, Tg: 145.4 ± 33.5 mm2; Figures
4H, 4J, and 4L) were prominently increased in CaMKII-tTA
Dox() Tg mice. In addition, cortical lamination was disrupted
in CaMKII-tTA Dox() Tg mice, as indicated by the immuno-
histochemical localization of Cux1-positive layer II/III neurons
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Figure 4. Activation of the mTORC1 Pathway in Postmitotic Neurons in Immature Mice
(A) Transgenic strategy for conditional expression of active mTOR kinase by the Tet-Off system. Expression of active mTOR depends on binding of tTA to the TRE
promoter. The CaMKII promoter drives tTA expression in postmitotic excitatory neurons of the forebrain.
(B) Cumulative survival curves for CaMKII-mTOR Dox() Tg (red line) and control (blue line) mice. Inset: typical appearances of control (left) and CaMKII-mTOR
Dox() Tg mice (right).
(C) Age-dependent change in active mTOR expression in CaMKII-mTOR Dox() Tg mice. Cortical lysates from CaMKII-tTA Dox() Tg mice at the designated
ages were prepared and immunoblotted with antibodies against FLAG and b-actin.
(D) Selective activation of the mTORC1 pathway in CaMKII-tTA Dox() Tg mice. Increased phosphorylation of S6K1 at Thr-389 was seen in the protein extract
from CaMKII-mTOR Dox() Tg cortex at P14 compared with that from the control. However, phosphorylation of Akt at Ser-473 was not affected by active mTOR
expression.
(E and F) Distribution of phosphorylated S6 protein in control and CaMKII-mTOR Dox() Tg brains. The regional specificity of activation of the mTORC1 pathway
was examined by immunohistochemistry of phosphorylated S6 protein at Ser-235/236. In CaMKII-mTOR Dox() Tg mice, an increased number of immuno-
positive neurons were detected in the cerebral cortex and hippocampus.
(G–J) Cortical hypertrophy in CaMKII-mTOR Dox() Tg mice. Shown are nissl-stained coronal sections of cerebral cortices from control and CaMKII-mTOR
Dox() Tg mice at P15. Both cortical thickness (G and I) and neuronal soma size (H and J) of CaMKII-mTOR Dox() Tg mice were increased compared with those
of the control.
(K and L) Quantification of cortical thickness and neuronal soma size of control and CaMKII-mTOR Dox() Tg mice. Values are means ± SD. *p < 0.001 (n = 3),
**p < 1059 (control: n = 201; Tg: n = 132), Student’s t test.
(M) Abnormal cortical structure in CaMKII-mTOR Dox() Tg mice. Cux1-positive cortical layer II/III neurons were scattered throughout the cortex in CaMKII-
mTOR Dox() Tg mice, indicative of impaired neuronal migration.
Scale bars, 1 mm (E and F), 200 mm (G and I), 50 mm (H and J), and 100 mm (M).sparsely distributed throughout the cortex (Figure 4M). These
results demonstrate that activation of the mTORC1 pathway in
postmitotic neuron results in dysregulation of neuronal cell size
and migration, leading to macrocephaly with abnormal cortical
cytoarchitecture.
Neuronal hypertrophy and impaired neuronal migration by
mTORC1 activation were also confirmed by in utero electropo-Cration experiments. When cortical progenitors at E14 were
transfected with EGFP-expressing plasmid, EGFP-labeled neu-
rons migrated from the ventricular zone to the pial surface of the
cortex (Figure 5A). When cotransfected with wild-type mTOR-
expressing plasmid, the EGFP-labeled neurons normally
migrated to the pial surface (Figure 5B), suggesting that overex-
pression of mTOR per se does not affect the neuronal migrationell Reports 7, 1626–1639, June 12, 2014 ª2014 The Authors 1631
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or cell size. In sharp contrast, cortical neurons expressing active
mTOR failed to migrate to the pial surface, remaining in the inter-
mediate zone (Figure 5C). In addition, active mTOR-expressing
neurons showed increased soma size compared with the control
(inset in Figures 5A–5C). After transfection of active mTOR into
the embryonic cortex, acute administration of rapamycin
(5 mg/kg) to the pregnant mother restored both impaired
neuronal migration and neuronal hypertrophy (Figure 5D).
Furthermore, knockdown of raptor by small hairpin RNA
(shRNA) also rescued both impaired neuronal migration and
increased cell size induced by active mTOR expression (Fig-
ure 5E). The target specificity of raptor knockdown was
confirmed by the coexpression of knockdown-resistant human
raptor, which reversed the phenotypes to abnormal migration
and enlarged soma (Figure 5F). Therefore, we can conclude
that impaired neuronal migration and cell size regulation can
be attributed largely to specific activation of mTORC1 signaling.
As for neuronal hypertrophy, we identified S6K1 and S6K2 as
possible targets of mTORC1 signaling for neuronal cell size
regulation. Neuronal hypertrophy induced by active mTOR
expression was rescued by knockdown of S6K1 and S6K2 (Fig-
ure 5G), suggesting that the mTORC1-S6K pathway may be
important for neuronal cell size regulation.
Activation of the mTORC1 Pathway in Adulthood
Given that CaMKII-mTOR Dox() Tg mice exhibited growth
retardation and postnatal lethality, we tried to activate the
mTORC1 pathway in adulthood. To avoid developmental
perturbation in the forebrain, we suppressed active mTOR
expression by doxycycline administration until 3 weeks of age
in Tg mice (Figure 6A). Hereafter, these mice are referred to
as CaMKII-mTOR Dox3w Tg mice. TRE-mTORSL1+IT/+ mice
that received doxycycline in the same way as the CaMKII-
mTOR Dox3w Tg mice were used as experimental control ani-
mals. After withdrawal of doxycycline at 3 weeks of age, we
could detect a gradual increase of active mTOR expression in
the cerebral cortex of CaMKII-mTOR Dox3w Tg mice after
5 weeks of age (Figure 6C). Excessive phosphorylation of
S6K1 was obvious at 6 weeks of age (Figure 6C), and hyper-
phosphorylation of S6 protein was restricted to the forebrain,
including the cerebral cortex and hippocampus, in CaMKII-
mTOR Dox3w Tg mice (Figures 6D and 6E). In contrast, the
phosphorylation level of Akt at Ser-473 was not changed by
active mTOR expression or rapamycin administration (Figures
S4A and S4B). Therefore, the mTORC1 pathway, but not
mTORC2, was spatiotemporally hyperactivated by doxycy-Figure 5. Impaired Neuronal Migration and Increased Neuronal Cell Si
(A–C) Cortical neurons expressing EGFP or wild-type mTOR migrated appropria
expression of active mTOR mutant resulted in impaired neuronal migration (C) a
(D) Administration of rapamycin after introduction of active mTOR mutant compl
(E) Knockdown of raptor also rescued both impaired migration and increased ce
(F) The target specificity of raptor knockdown was confirmed by coexpression
Together, these data clearly demonstrate the specific involvement of mTORC1 i
(G) Knockdown of S6K1 and S6K2 restored increased cell size to the normal state
size regulation.
(H) Quantification of neuronal soma size. Values are means ± SD (n = 50 from 4
(I) Quantification of distribution of cortical neurons. Values are means ± SD (n =
Ccline-regulated expression of active mTOR in CaMKII-mTOR
Dox3w Tg mice.
Alongwith activemTOR expression, CaMKII-mTORDox3w Tg
mice showed hypoactivity from 6 weeks of age, and all of them
died between 6 and 7 weeks of age (Figure 6B). Similarly to
CaMKII-mTOR Dox() Tg mice, CaMKII-mTOR Dox3w Tg mice
showed cortical hypertrophy (Figures 6F–6K) with thickened
cerebral cortex (Figures 6F, 6H, and 6J) and enlarged neuronal
soma (Figures 6G, 6I, and 6K) at 6–7 weeks of age. Unlike
CaMKII-mTOR Dox() Tg mice, the cortical lamination was
almost preserved, as shown by the distribution of Cux1-positive
layer II/III neurons properly located in the upper layer of the cor-
tex (Figure 6L). These results demonstrate that activation of
mTORC1 pathway in adulthood provokes macrocephaly without
affecting the arrangement of the cortical layer during brain
development.
Epileptic Seizures in CaMKII-mTOR Tg Mice
We explored a direct cause of lethality of CaMKII-mTOR Dox3w
Tg mice by closely observing their behavior, especially during
epileptic seizures, which are frequently seen in TSC patients.
We observed frequent spontaneous seizures in CaMKII-mTOR
Dox3w Tg mice 3–4 weeks after withdrawal of doxycycline. Sei-
zures were characterized by unilateral forelimb clonus followed
by bilateral forelimb clonus and falling (Movies S1 and S2).
During the seizures, local field potentials (LFPs) recorded from
the bilateral parietal cortices of freely moving CaMKII-mTOR
Dox3w Tg mice showed rhythmic burst discharges lasting tens
of seconds (Figure 7A). In addition, we could observe clear differ-
ences in LFPs between the right and left cortices during seizures
(Figures 7A and 7B), indicating that abnormal neuronal dis-
charges could be localized during the course of seizures, as
reported in patients with TSC (Bebin et al., 1993). During the in-
terictal period, active exploration was associated with bilateral
synchronous theta oscillation of the LFP in CaMKII-mTOR
Dox3w Tg mice, which was almost similar to that in control
mice (Figure 7C). However, multifocal, large interictal spikes
were frequently observed in CaMKII-mTOR Dox3w Tgmice (Fig-
ures 7D and 7E), but not in the control. These results suggest that
the characteristic patterns of LFP during ictal and interictal
periods in CaMKII-mTOR Dox3w Tg mice are similar to those
in patients with TSC. It should be noted that hypertrophy of the
CaMKII-mTOR Dox3w Tg cortex was suppressed by chronic
administration of doxycycline or rapamycin (Figures S4C and
S4D). Administration of doxycycline or rapamycin also inhibited
epileptic seizures and postnatal lethality (data not shown).ze by mTORC1 Activation
tely near the pial surface of the cortex with normal cell size (A and B), whereas
nd increased cell size (C, inset).
etely rescued both impaired migration and increased cell size.
ll size.
of knockdown-resistant human raptor, which abolished rescued phenotypes.
n both neuronal migration and cell size regulation.
, indicating that the hyperactivated mTOR-S6K pathway impaired neuronal cell
mice).
8 slices from 4 mice)
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Figure 6. Activation of the mTORC1 Pathway in Adulthood
(A) Schematic diagram for reversible expression of active mTOR in CaMKII-mTOR Tg mice. Administration of Dox until 3 weeks of age prevents tTA from binding
to TRE, silencing active mTOR expression. Withdrawal of Dox reactivates tTA binding to TRE, thereby inducing active mTOR expression in adulthood.
(B) Cumulative survival curves for CaMKII-mTOR Dox3w Tg (red line) and control (blue line) mice.
(C) Time-course expression profile of active mTOR protein. Cortical lysates at indicated age were immunoblotted with antibodies against FLAG, p-S6K1, S6K1,
and b-actin. Dox (+) indicates CaMKII-mTOR Tg mice that were continuously administered Dox.
(D and E) Distribution of phosphorylated S6 protein in control and CaMKII-mTOR Dox3w Tg brains. Enhanced phosphorylation of S6 protein at Ser-235/236 was
observed in the forebrain of CaMKII-mTOR Dox3w Tg mice.
(F–I) Nissl-stained coronal sections of cerebral cortices from control and CaMKII-mTOR Dox3w Tg mice at 7 weeks of age. Similar to what was observed in
CaMKII-mTOR Dox() Tg mice, both cortical thickness (F and H) and neuronal soma size (G and I) were increased in CaMKII-mTOR Dox3w Tg mice.
(J and K) Quantification of cortical thickness and neuronal soma size of control and CaMKII-mTOR Dox3w Tg mice. Values are means ± SD. *p < 104 (n = 3),
**p < 10105 (control: n = 247; Tg: n = 201), Student’s t test.
(L) Normal cortical layering in CaMKII-mTOR Dox3w Tg mice. Despite cortical hypertrophy, Cux1-positive cortical neurons were located properly at layers II/III in
CaMKII-mTOR Dox3w Tg mice.
Scale bars, 1 mm (D and E), 200 mm (F and H), 50 mm (G and I), and 100 mm (L). See also Figure S4.Therefore, these phenotypes can be attributed largely to hyper-
activation of the mTORC1 pathway.
CaMKII-mTOR Dox() Tg mice also displayed spontaneous
behavioral seizures around 2 weeks of age, accompanied by
abnormal LFPs similar to those observed in CaMKII-mTOR
Dox3w Tg mice (Figure S5; Movies S3 and S4). These were
sometimes followed by tonic extension of four limbs toward
the caudal direction. This tonic seizure lasted for several
minutes, and although some mice gradually recovered, other
mice died without recovery. Therefore, activation of the
mTORC1 pathway in the forebrain is sufficient to induce fatal
epileptic seizures.1634 Cell Reports 7, 1626–1639, June 12, 2014 ª2014 The AuthorsNeurodegeneration of Cortical Neurons in CaMKII-
mTOR Tg Mice
As embryonic activation of the mTORC1 pathway leads to
apoptotic cell death of neuronal progenitors, we tested whether
mTORC1 signaling in postmitotic neurons regulates neuronal
cell survival. We did not detect excessive immunoreactivity of
CC3 in CaMKII-tTADox() Tg cortex at P12 (Figure S6), suggest-
ing that mTORC1 activation may not enhance apoptotic cell
death in postmitotic cortical neurons.
Since mTOR activity is upregulated in many types of human
neurodegenerative diseases, we examined the possible
involvement of the mTORC1 pathway in neurodegeneration.
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Figure 7. Epileptic Seizure and Neurode-
generation in CaMKII-mTOR Dox3w Tg
Mice
(A–E) Epileptic seizure in CaMKII-mTORDox3w Tg
mice.
(A and B) LFPs recorded from freely moving
CaMKII-mTOR Dox3w Tg mice at 7 weeks of age
during seizures. The sections of LFP traces
shaded by a green rectangle in (A) are enlarged in
(B). A clear difference in LFP between the right and
left hemispheres was observed during seizures.
(C) LFPs recorded from freely moving control and
CaMKII-mTORDox3w Tgmice during exploration.
Black and blue traces represent LFPs of right and
left parietal cortices, respectively. No difference
was observed in synchronous theta oscillations
between the two genotypes.
(D and E) Frequent bilateral large interictal spikes
in CaMKII-mTOR Dox3w Tg mice. Bilateral large
interictal spikes indicated by green rectangles in
(D) consist of sharp spikes and waves in left traces
in (E).
(E) Variable types of interictal spikes observed in
CaMKII-mTOR Dox3w Tg mice. Both bilateral (left
traces) and unilateral (right traces) interictal spikes
were observed in the single CaMKII-mTORDox3w
Tg mouse.
(F–I) Neurodegeneration in CaMKII-mTOR Dox3w
Tg cortex.
(F and G) Cortical sections from control and
CaMKII-mTOR Dox3w Tg mice at 7 weeks of age
were stained with an antibody against ubiquitin
(green). Accumulation of ubiquitin-positive cyto-
plasmic inclusions was readily detectable in
CaMKII-mTOR Dox3w Tg mice (G). Dotted lines
depict boundaries of individual neurons.
(H and I) Microglial cells in the cerebral cortex were
stained with an antibody against Iba1 (green), a
marker of microglial cells. Cell nuclei were stained
with TO-PRO-3 (blue). Characteristic changes in
morphology of microglial cells were observed in
CaMKII-tTA Dox3w Tg mice with enlarged cell
bodies and short protrusions (I). Inset: high-power
images of microglial cells.
Scale bars, 10 mm (F, G, and inset in H and I) and
200 mm (H and I). See also Figures S5–S7 and
Movies S1, S2, S3, and S4.We stained cortical sections from control and CaMKII-mTOR
Dox3w Tg mice with anti-ubiquitin antibody, which can iden-
tify cytoplasmic inclusions, a characteristic feature of neuro-
degeneration. In CaMKII-mTOR Dox3w Tg cortex, a large
number of ubiquitin-positive cytoplasmic inclusions were
found in many neurons, especially in the pyramidal neurons
in layers II/III and V (Figure 7G), whereas ubiquitin-positive
inclusions were rarely detected in the control cortexCell Reports 7, 1626–163(Figure 7F). Rapid accumulation of cyto-
plasmic inclusions was also found in
CaMKII-mTOR Dox() Tg mice at P12
(Figures S7A and S7B), indicative of
involvement of mTORC1 signaling in
neurodegeneration.Microglial cells are resident immune cells in the CNS and are
involved in the pathogenesis of neurodegenerative diseases as
well as in the engulfment of damaged cells (Perry et al., 2010).
They undergo increased proliferation and drastic morphological
changes in response to neuronal degeneration or inflammation.
We examined the activation ofmicroglial cells by staining cortical
sections with Iba1, a microglial cell marker. Microglial cells in the
control cortex showed relatively normal-sized cell bodies with9, June 12, 2014 ª2014 The Authors 1635
highly branched protrusions (Figures 7H and S7C). In contrast,
we found an increased number of microglial cells with enlarged
cell bodies and short processes in both CaMKII-mTOR Dox3w
Tg and CaMKII-mTOR Dox() Tg cortices (Figures 7I and
S7D), indicating that activation of microglial cells is associated
with neurodegeneration. These results support the notion that
activation of themTORC1 pathway in postmitotic neurons accel-
erates the accumulation of cytoplasmic inclusions, faithfully
recapitulating neurodegenerative diseases.
DISCUSSION
Since the brain is one of the most energy-consuming organs in
the body, mTOR has been assumed to play an important role
in neuronal functions. Aberrant activation of mTOR signaling in
the CNS has been implicated in many human neurological dis-
eases and has attracted considerable attention as a potential
therapeutic target using rapamycin analogs. Recently, several
mouse models for constitutive activation of mTOR signaling
have been generated by conditional deletion of either the Tsc1
or Tsc2 gene. In the embryonic cerebral cortex, hyperactivation
of mTOR signaling by deletion of Tsc1 leads to enhanced prolif-
eration of SVZ progenitors and cortical hypertrophy (Carson
et al., 2012; Magri et al., 2011). These phenotypes contrast
starkly with those observed in our Emx1-mTOR Tg mice, which
exhibited prominent apoptosis of cortical SVZ progenitors but
normal proliferation during corticogenesis. A reduction in the
number of SVZ progenitors may deplete the progenitor pool, re-
sulting in cortical atrophy in adulthood. One possible explanation
for the discrepancy between these phenotypes is that the acti-
vation level of mTOR signaling may differ between conditional
Tsc1 knockout and Emx1-mTOR Tg mice. In conditional Tsc1
knockout mice, the activation level of mTOR signaling critically
depends on the expression level of endogenous mTOR kinase,
and thus its activation may vary in different brain regions and
developmental periods. In contrast, wewere able to directly acti-
vate the mTORC1 pathway in a spatiotemporally controlled
manner by using active mTOR kinase in our Tg mice. Therefore,
the molecular and physiological phenotypes observed in this
study can be attributed largely to hyperactivation of themTORC1
pathway.
Although mTOR has a cell-protective function in general,
inappropriate activation of mTOR signaling can make cells
sensitive to apoptosis, especially quiescent cells such as neu-
rons. In fact, microcephaly-capillary malformation syndrome is
caused by a mutation in the STAMBP gene, which is associated
with aberrant activation of the mTORC1 pathway and apoptotic
cell death (McDonell et al., 2013). TUNEL-positive apoptotic
cells have been detected in cortical tubers from human patients
with TSC (Maldonado et al., 2003), as well as in the mouse
model of TSC (Zeng et al., 2007). However, the molecular mech-
anism that underlies apoptotic neuronal cell death by mTORC1
activation is largely unknown. We identified HIF-1a as a poten-
tial downstream target that triggered apoptosis of neuronal
progenitors in Emx1-mTOR Tg cortex. Activated mTOR upre-
gulated HIF-1a expression, presumably by enhanced protein
synthesis and/or stabilization by direct interaction with the
mTORC1 complex through the TOS motif of HIF-1a. Further-1636 Cell Reports 7, 1626–1639, June 12, 2014 ª2014 The Authorsmore, we confirmed elevated expression of p21, a downstream
HIF-1 target gene that is involved in cell-cycle control. It was
previously demonstrated that during hypoxia, enhanced activa-
tion of HIF-1a by mTORC1 could be reversed by treatment with
rapamycin (Land and Tee, 2007). In line with these observations,
genetic studies using embryonic stem cells lacking HIF-1a
also showed decreased levels of apoptosis (Carmeliet et al.,
1998). Therefore, HIF-1 signaling may provide a possible mech-
anistic link between apoptosis of neuronal cells and mTORC1
signaling.
In contrast to the cortical atrophy observed in Emx1-mTOR Tg
mice,mTORC1activation inpostmitotic neurons inducedcortical
hypertrophy and increased neuronal cell size in CaMKII-mTOR
Tg mice. Previous studies showed that suppression of DISC1,
the schizophrenia susceptibility gene, perturbs neuronal devel-
opment and cell size regulation via hyperactivation of the
mTORC1 pathway (Kim et al., 2009). Abnormal activation of
mTOR signaling has been detected in cytomegalic neurons of
patients with TSC (Orlova and Crino, 2010) or cortical dysplasia
(Ljungberg et al., 2006). More recently, de novo somatic
mutations of mTOR (C1483Y) were identified in a patient with
hemimegalencephaly, a rare congenital disorder characterized
by overgrowth of one-half of the brain (Lee et al., 2012). Patholog-
ical samples from the affected patient showed elevated phos-
phorylation of S6 protein, suggesting that the C1483Y mutation
is a novel spontaneous gain-of-function mutation of mTOR. In
contrast, inactivation of mTORC1 in the developing brain was
shown to cause a reduction in cell size and number, resulting in
microcephaly in late embryogenesis (Cloe¨tta et al., 2013).
Together with these studies, our data support the notion that
cortical hypertrophy and enlarged neurons are caused by gain
of function of mTORC1 signaling.
Generally, epileptic seizures are associated with human
neurological diseases that involve structural abnormalities in
the brain. In TSC, cortical tubers that include ectopic neurons
with abnormal morphology and migration are assumed to serve
as the foci of epileptic seizures. In this work, although the
CaMKII-mTOR Dox3w Tg mice experienced fatal epileptic sei-
zures, they did not form any detectable cortical tuber-like struc-
tures. It is possible that intracranial hypertension due to cortical
hypertrophy may cause epileptic seizures in CaMKII-mTOR
Dox3w Tg mice. In the cortex of Tsc1 conditional knockout
mice, both abnormal brain structure and epileptic seizures could
be suppressed by rapamycin treatment, but epileptic seizures
recurred shortly after withdrawal of rapamycin without structural
abnormalities of the brain (Magri et al., 2011). Pten deletion in
adult-generated granule neurons of the hippocampal dentate
gyrus hyperactivates mTOR signaling and drives aberrant circuit
formation during epileptogenesis (Pun et al., 2012). Therefore, it
may also be possible that deregulation of synaptic activity and
neural circuit formation by aberrant activation of mTOR signaling
are involved in induction of epileptic seizures.
In parallel with cortical hypertrophy and epilepsy, we observed
neurodegenerative disease-like symptoms in the cortical neu-
rons of both CaMKII-mTOR Dox() Tg and CaMKII-mTOR
Dox3wTg mice. Accumulation of cytoplasmic inclusions accom-
panied by neurodegeneration has been also detected in cortical
neurons and cerebellar Purkinje cells in mice lacking the
autophagy-related gene Atg5 (Hara et al., 2006) or Atg7 (Ko-
matsu et al., 2006). Autophagy is a bulk protein degradation pro-
cess, and activation of mTORC1 crucially suppresses the forma-
tion of autophagosomes by phosphorylating ULK1 and Atg13,
resulting in the accumulation of various aggregate-prone pro-
teins (Mizushima and Komatsu, 2011). However, the onset of
cytoplasmic accumulation occurs much later in autophagy-defi-
cient mice than in CaMKII-mTOR Dox() Tg mice. In addition to
the suppression of autophagy, enhanced protein synthesis by
mTORC1 activation may accelerate the onset of accumulation
of the cytoplasmic inclusions in CaMKII-mTOR Dox() Tg
mice. Alternatively, epileptic seizure may induce neurodegener-
ation by currently unknown mechanisms. Since epileptic seizure
has been implicated in neuronal cell death (Pitka¨nen and Luka-
siuk, 2011), the frequent seizures in CaMKII-mTOR Dox() Tg
mice may promote a progression of neurodegeneration, which
in turn deteriorates epileptic seizures.
Our findings suggest that mTOR signaling in the CNS adopts
different downstream effectors for neuronal survival during the
embryonic and adult stages. Such stage-specific functional dif-
ferences in mTOR signaling may contribute to a wide range of
neurological diseases. In principle, the mutant mice generated
in this study can be applicable to every tissue and cell type,
and therefore will provide a better understanding of the molecu-
lar mechanisms of mTOR-related human diseases.EXPERIMENTAL PROCEDURES
Generation of Tg Mice
The animal experiments were conducted in accordance with the guidelines
of The University of Tokyo. The active mutant of rat mTOR kinase was isolated
as described previously (Ohne et al., 2008). For CAG-mTORSL1+IT Tg mice,
a transgene was constructed by inserting the mTORSL1+IT mutant into the
pCALNL5 vector, which directs gene expression under the control of the
CAG promoter in response to Cre-loxP recombination (Figure 1A). For TRE-
mTORSL1+IT Tg mice, the mTORSL1+IT mutant was placed downstream of
TRE, and the chicken b-globin insulator sequence was introduced at the 50
ends of the transgene (Figure 4A). These transgenes were linealized and sepa-
rately injected into the pronuclei of C57BL/6 embryos. Founder Tg mice were
crossed with C57BL/6 mice, and the established Tg mice were genotyped by
genomic PCR analysis using a pair of primers designed to amplify the portion
of rat mTOR gene (50-CAAGG ATGAC GACGA TAAGG-30 and 50-TGCCA
TCTCC ATGAC AACTG-30). Emx1-cre knockin mice were generated as
described previously (Kassai et al., 2008). CaMKII-tTA Tg mice were obtained
from The Jackson Laboratory (Mayford et al., 1996). The genetic background
of the Tgmice used in this study was a hybrid of C57BL/6, DBA/2, and ICR.We
confirmed that Tg mice with the C57BL/6 background gave essentially the
same results.
Drug Administration
Doxycycline hyclate (Sigma) was dissolved in drinking water (200 mg/l) and
supplied to pups and their parents until 3 weeks of age. Rapamycin (R-
5000; LC Laboratories) was prepared as a 25 mg/ml stock solution in ethanol.
Before each administration, the stock solution was diluted in 5% Tween-80,
5% polyethylene glycol 400 (0.5–1.5 mg/ml). Rapamycin was given at
5 mg/kg intraperitoneally once per day for more than 4 weeks from 3 weeks
of age.
Western Blot Analysis
Western blot analysis was performed as described previously (Kassai et al.,
2008). Additional details of the methods and antibodies used can be found
in Supplemental Experimental Procedures.CHistology
Histological analysis was performed as described previously (Kassai et al.,
2008). Supplemental Experimental Procedures contains detailed information
regarding Nissl staining, b-galactosidase staining, and immunohistochemical
analysis.
In Utero Electroporation
The protocols used for in utero electroporation experiments are detailed in
Supplemental Experimental Procedures.
LFP Recording in Freely Moving Mice
For LFP recording, we used immature and adult CaMKII-mTOR Tg mice and
their control littermates. The immature mice were P15 on the day of electrode
implantation and adult mice were 7 weeks old, which corresponds to the
timing 4 weeks after withdrawal of doxycycline. Under isoflurane anesthesia
(1.5%), recording electrodes (polyurethane-coated stainless-steel wire with
100 mm in diameter) were placed on the bilateral parietal cortex (1 mm lateral,
1 mm posterior to bregma for immature mice, and 2 mm lateral, 2 mm poste-
rior to bregma for adult mice). Two microscrews with cables were positioned
in the occipital bone. One was used as a ground and the other was used as an
indifferent electrode. Electrodes were fixed to the skull with dental acrylic
cement. Body temperature was maintained at 37C throughout the surgery
with the use of a heating blanket. Four days after implantation, the LFPs of
bilateral parietal cortex were recorded in freely moving mice for 2 hr per
day until the mice died. Signals were amplified (MEG-5200; Nihon-Koden)
and digitized (PowerLab; AD Instruments) for analysis with the use of
MATLAB (The MathWorks).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.04.048.
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